Products
Pre-made Abrezekimab benchmark antibody ( Fab, anti-IL13 therapeutic antibody, Anti-IL-13/P600 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-004
Pre-Made Abrezekimab biosimilar, Fab, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Abrezekimab (formerly VR 942) a biologic immunomodulatory product, is being developed by UCB and Vectura Group for the treatment of severe inflammatory.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-004-1mg | 1mg | 3090 | ||
| GMP-Bios-ab-004-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-004-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-004-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Abrezekimab biosimilar, Fab, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody |
| INN Name | Abrezekimab |
| Target | IL13 |
| Format | Fab |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | UCB |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Asthma |
| Development Tech | na |
<